- Conditions
- Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
- Interventions
- Lecanemab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Volunteers
- Interventions
- Lecanemab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
- Interventions
- lecanemab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • St Louis, Missouri + 1 more
- Conditions
- Early Alzheimer's Disease
- Interventions
- Lecanemab IV, Placebo, Lecanemab SC
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 1,906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 112
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 84 more
- Conditions
- Alzheimer's Disease
- Interventions
- E2814, Lecanemab, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Bradenton, Florida + 15 more